Comparison tool
Abaloparatide vs Oxytocin side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Abaloparatide | Oxytocin |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | Tymlos, BA058 | Pitocin, Syntocinon, The Love Hormone |
| FDA approved | Yes | Yes |
| Clinical status | FDA approved for osteoporosis in postmenopausal women and in men at high fracture risk; the male indication was added in December 2022.
| FDA approved for labor and postpartum use; other uses remain under research
|
| What to expect | Osteoporosis, bone health, fracture risk reduction | Social bonding, anxiety, trust, emotional wellbeing |
| How it works | Abaloparatide is described as a PTHrP analog that engages the PTH type 1 receptor. Compared with teriparatide, the source reports a different receptor-binding profile, including preference for an RG-bound receptor state and a more transient signal. The proposed rationale is an anabolic bone effect through osteoblast-driven formation with less stimulation of resorption and calcium elevation than might occur with longer PTHR1 signaling. | Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways. |
| Typical dosing | 80 mcg daily · Once daily · Subcutaneous injection daily | 10-24 IU intranasal as needed · As needed · Intranasal |
| Research dosing | 80 mcg subcutaneous daily · Once daily · Maximum 2 years · Subcutaneous injection daily | 10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research) |
| Typical duration | Maximum 2 years | Single dose or short-term use |
| Administration | Subcutaneous injection daily | IV in obstetric labeling; intranasal in research contexts |
| Timing | Morning or as directed With or without food | As needed in studied social or bonding contexts With or without food |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+4 more
|
+4 more
|
| Research summary | The source highlights randomized clinical evidence from the ACTIVE phase 3 trial in more than 2,400 postmenopausal women, comparing abaloparatide with placebo and open-label teriparatide over 18 months. It reports substantial reductions versus placebo in new vertebral and nonvertebral fractures and a favorable comparison with teriparatide for major osteoporotic fractures in that dataset. It also notes cardiovascular safety analyses, transient heart-rate increases as an on-label class effect, and ATOM trial bone-density data that supported the later male osteoporosis indication. | The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.